Recently funded awards

Advanced Clinician Scientist Fellowships

Elspeth Payne, University College London
Early diagnosis and Personalised therapy for myelodysplastic syndromes

Clinician Scientist Fellowships

Hamid Ali, University of Cambridge
Dissection of diverse checkpoint programs to target immunotherapy in triple-negative breast cancer

Tobias Janowitz, University of Cambridge
Targeting the connected metabolic and immune responses to pancreatic cancer to improve outcomes for patients

Melinda Czeh, University of Oxford
The role of haematopoietic stem cell bias in acute leukaemia initiation

Ahsan Akram, University of Edinburgh
Fibroblast activation protein expressing cancer associated fibroblasts from lung cancer as imaging biomarkers for immunotherapy stratification

Sheeba Irshad, King's College London
Chemokine dependent immune tumour cell cross-talk in chemotherapy resistant early triple negative breast cancers

Pre-doctoral Research Bursaries

Alison Berner, University College London
Harnessing the use of molecular signatures in research and clinical settings

Samantha Downie, University of Edinburgh
How does size, site and type of bony metastasis in the proximal femur impact on lesion progression and risk of fracture?

Janice Miller, University of Edinburgh
Elucidating the molecular mechanisms and clinical consequences of skeletal muscle loss in cancer cachexia

Benjamin Stewart, University of Cambridge
Understanding the spatially-resolved global immunological architecture and antibody effector function of the renal cell carcinoma microenvironment

Ali Abdulnabi Mohamed, University of Leicester
In-depth analysis of somatic copy number alterations in gastroesophageal adenocarcinomas and developing liquid biopsy to aid therapeutic stratification and disease monitoring

Nickola Pallin, University College London
Identifying therapeutic radiographers’ barriers in providing lifestyle advice to cancer survivors

Robert Watson, University of Oxford
How does metastatic melanoma shape circulating T-cell clonality and does this influence response to checkpoint inhibitors?

CRUK/Pathological Society Pre-doctoral Research Bursaries

John Griffin, University of Sheffield
Exploring heterogeneity in bladder cancer

Alice Huskinson, University of Leeds
Improving the personalized pre-surgical treatment of patients with advanced colon cancer through the molecular analysis of EGFR pathway

Postdoctoral Research Bursaries

Mark Bullock, University of Southampton
The role of P53 in exosomal microRNA export: implications for tumour/stroma cross-talk in colorectal cancer

David Pinato, Imperial College London
Phenotypic characterisation of the anti-tumour immune response following loco-regional therapy of hepatocellular carcinoma

Colin Steele, University of Glasgow/Beatson Inst
Are CXCR2 positive cells important in generating an immunosuppressive metastatic niche for colorectal metastatic disease in the liver?

Hester Franks, University of Nottingham
Role of adenosine, a new metabolic immune checkpoint for cancer immunotherapy in human myeloid lineage cells

Crispin Hiley, Francis Crick Institute
Systemic neo-antigen specific CD4 T cell responses during ant-PDL1 therapy in non-small cell lung cancer (NSCLC)

Biomarker Project Awards

Duncan Gilbert and David Sebag-Montefiore, University of Leeds
PLATO: Personalising Radiotherapy in Anal Cancer - integrated sample collection and biomarker validation application

Early Phase and Feasibility Study Awards

Lynley Marshall and Pamela Kearns, University of Birmingham
E-smart: European proof of concept therapeutic stratification trial of molecular anomalies in relapsed or refractory tumours in children

Francis Mussai, University of Birmingham
PARC: A Phase II study evaluating the activity of Pegylated recombinant human Arginase (BCT-100)

Maria Hawkins, University of Oxford
CEDAR: Chemoradiation with Enadenotucirev as a radiosensitiser in locally advanced colorectal cancer

Late Phase Clinical Trial Awards

Meriel Jenney and Henry Mandeville, University of Birmingham
FaR-RMS: A multiarm-multistage study for children and adults with localised and metastatic Frontline and Relapsed RhabdoMyoSarcoma

Kwee Yong and Mark Cook, University of Leeds
Myeloma XV: RADAR: Risk Adapted therapy Directed According to Response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell translation (TE)

Prospective Sample Collection Awards

Hisham Mehanna and Paul Nankivell, University of Birmingham
CompARE Collect: Prospective biological sample collection from patients with intermediate and high-risk oropharyngeal cancer recruited to CompARE randomised controlled trial

Mark Middleton, University of Oxford
Sample collection associated with the INTERIM trial of intermittent BRAF targeted therapy in advanced melanoma

Strategic Initiatives

Louis Chesler and Darren Hargrave, The Institute of Cancer Research, London
Stratified Medicine Paediatrics – SMPaeds: Genomic characterisation of relapsed paediatric cancers for diagnostics and stratified therapy

Biotherapeutics Project Awards

Dr Michael Chapman, University of Cambridge
Identification of a novel monoclonal antibody target in myeloma

Dr Amin Hajitou, Imperial College London
Investigation of a harmless prokaryotic viral vector for targeted intravenous cytokine gene therapy of cancer

Prof Aymen Al-Shamkhani, University of Southampton
Targeting TNFRSF25 to promote anti-tumour immunity

Dr Simon Leedham, University of Oxford
Therapeutic manipulation of GREM1 signalling in colorectal cancer

Biotherapeutics Programme Awards

Prof Mark Cragg and Dr Steven Beers, University of Southampton
Understanding Fc gamma receptors to improve antibody immunotherapy

Small Molecule Project Awards

Prof Anthony Chalmers, University of Glasgow
Evaluating the therapeutic potential of PARG inhibition in glioblastoma and further elucidating the mechanism(s) of action

Prof Neil Carragher, University of Edinburgh
Mechanistically informed Phenotypic Screening to Advance New Therapeutic Treatments for Oesophageal Cancer Patients

Dr Daniel Tennant, University of Birmingham
Validation of peptidyl arginine deiminase 2 (PADI2) as a therapeutic target in multiple myeloma

Prof Adrian Harris, University of Oxford
Small molecule carbonic anhydrase IX inhibitors for the treatment of hypoxic tumours

Dr Walid Khaled, University of Cambridge
Disrupting BCL11A protein-protein interactions as a therapeutic approach for TNBC and LUSC

Dr Tim Fenton, University of Kent
Generation and characterization of a humanized APOBEC3 mouse: a crucial tool for target validation and preclinical development of APOBEC inhibitors as anti-cancer drugs

Dr Katherine Finegan, University of Manchester
Developing a novel class of ERK5 inhibitors for the treatment of triple-negative breast cancer

Dr Kevin Myant, The University of Edinburgh
Target validation of the RNA splicing factor SRSF1

Early Detection Programme Awards

Professor Doug Easton and Dr Nitzan Rosenfeld, University of Cambridge and CRUK Cambridge Institute
Earlier Diagnosis in women at high risk of breast and ovarian cancer

Professor Eithne Costello, University of Liverpool
Detecting pancreatic cancer in the largest high-risk group for this disease: A top-down approach

Early Detection Project Awards

Dr Adam Mead, University of Oxford
Early detection of platelet biased HSCs in myelofibrosis and clonal haematopoiesis

Dr Valentine Macaulay, University of Oxford
Identifying a cancer IGF signature for early detection and risk reduction

Dr Yi Feng, University of Edinburgh
Systematic analysis of metabolic change in the earliest pre-neoplastic cell niche for identifying possible targets for early detection and intervention

Professor Attila Lorincz and Dr Belinda Nedjai, Queen Mary University of London
Non-invasive test for methylation classifiers to screen for cervical precancer in self-collected vaginal and urine specimens

Professor Ian Tomlinson, Professor Claus Andersen & Professor Colin Rees, University of Birmingham
Population-based early detection of colorectal cancer: a pilot to evaluate the use of circulating tumour DNA

Dr James Flanagan, Imperial College London
Early Diagnosis for Ovarian Cancer using commercial loyalty card data and purchase behaviours

Professor Chris Probert, University of Liverpool
Volatile organic compounds for the detection of colorectal cancer: VODECA

Dr Simon Leedham & Professor Trevor Graham, University of Oxford and Barts Cancer Institute
Early detection of colorectal cancer risk in patients with inflammatory bowel disease

Professor David Baldwin, Nottingham University Hospitals NHS Trust
SELECT – Selection of eligible people for lung cancer screening using electronic primary care data: development of new risk prediction models

Professor Timothy Aitman, University of Edinburgh
Multiplex methylation analysis of cell-free DNA for early cancer diagnosis

Dr Tatjana Crnogorac-Jurcevic, Queen Mary University of London
Evaluation of early pancreatic cancer biomarkers in pre-diagnostic urine specimens

Dr John Timms, University College London
Early detection of ovarian, pancreatic and colorectal cancers using novel biomarker modelling approaches

Dr Sylvain Ladame, Imperial College London
Engineering and validation of a modular and non-invasive screening tool for cancer based on automated microRNA profiling from whole blood with paper-hydrogel electrochemical sensors

Dr Chunxiao Song, University of Oxford
Comprehensive epigenetic profiling of cell-free DNA for early cancer detection

Mr Christos Kontovounisios & Dr Fernando Bello, Imperial College London
Improving early detection of colorectal cancer through an innovative highly realistic simulation environment

Dr Janet Risk, University of Liverpool
Early detection of oral cancer using infrared imaging

Early Detection OHSU Project Awards

Dr Abdenour Soufi and Dr Jungsun Kim, University of Edinburgh and OHSU
Reprogramming pancreatic cancer to discover early diagnosis biomarkers

Dr Chunxiao Song and Dr Thuy Ngo, University of Oxford and OHSU
Cell-free epigenome and transcriptome sequencing for early detection of pancreatic and oesophageal cancer

Dr Daniel Munoz-Espin and Dr James Korkola, University of Cambridge and OHSU
Dissecting the role of the senescent secretome in tumorigenesis

Early Detection OHSU Spark Awards

Dr Gabriella Ficz and Dr Hisham Mohammed, Barts and the London School of Medicine and OHSU
Delineating early transformational events in Her2 positive breast cancer

Dr John Lizhe Zhuang and Professor Young Hwan Chang, University of Cambridge and OHSU
Deciphering the immune microenvironment in oesophageal adenocarcinoma and pre-cancerous lesions to a single cell resolution

Dr Sarah Bohndiek and Dr Vassiliki Tsikitis, University of Cambridge and OHSU
Hyperspectral Endoscopy Imaging for Early Detection of Precancerous Lesions in Average Risk and Inflammatory Bowel Disease Patients: Proof of Principle

Dr Richard Bryan & Dr Douglas Ward and Dr Timur Mitin & Dr Reid Thompson, University of Birmingham and OHSU
Amplicon deep sequencing of urinary DNA for the early detection of recurrence following chemo-radiotherapy for muscle-invasive bladder cancer (“AmpseqUr-RT”)

Early Detection Innovation Awards 

Sensor technology for liquid biopsy sandpit

Team EpiEnrich led by Charlie Massie at CRUK Cambridge Institute
Will enrich liquid biopsy samples by concentrating nucleosomes and then removing the bits of DNA that are bound to them.

Team ExoPop led by Dave Carter at Oxford Brookes University
Will identify the contents (defining signatures) of extracellular vesicles in liquid biopsies by popping them on a probe using current.

Team Quantum Leapers led by Melissa Mather at University of Nottingham
Will explore a new platform for analysing metabolomic profiles in liquid biopsies that uses a diamond sensor, which can create spectra like NMR.

Team TEP-eDx led by Beth Psaila at University of Oxford
Will identify characteristics and develop sorting techniques to capture tumour educated platelets from blood.

Drug Development Projects

Dr Sally Adams & Professor Lindy Durrant, Scancell Holdings plc
Exploratory development of a DNA vaccine encoding NY-ESO-1 epitopes as a first in human treatment for solid tumours including non-small cell lung cancer

Dr James Arnold & Professor James Spicer, Kings College London
Exploratory development of Heme Oxygenase-1 (HO1) inhibitor Tin Mesoporphyrin dichloride (SnMP) for a Phase I trial in combination with chemotherapy in advanced cancer

Preclinical Combinations Grants

Professor Anthony Chalmers, University of Glasgow
Combining the Akt inhibitor MK2206 with radiation to improve outcomes for patients with glioblastoma (jointly funded by Cancer Research UK and The Brain Tumour Charity)

Dr Helen Bryant, University of Sheffield
Radiosensitisation of NSCLC by the AURKA inhibitor Alisertib

Dr Emma Searle, University of Manchester
Targeting the Akt pathway with AZD5363 in combination with radiotherapy to improve tumour control in head and neck cancer

Career Development Fellowship

Chris Tape, University College London
Heterocellular APC Signalling in Colorectal Cancer

Siim Pauklin, University of Oxford
Molecular mechanisms regulating cancer stem cell formation and maintenance in pancreatic cancer

Senior Cancer Research Fellowship

Victoria Sanz-Moreno, Kings College London
Investigating Rho-kinase (ROCK) in melanoma progression and therapy response

Monika Gullerova, University of Oxford
Elucidating the mechanism of RNA dependent DNA damage response and its role in cancer

Programme Grants

Amanda Cross and Wendy Atkin, Imperial College London
Screening, Prevention and Diagnosis of Colorectal Cancer (renewal)

Project Grants

Richard Martin, Bristol
Evaluating the long-term effectiveness and cost-effectiveness of population-based screening and treatment for prostate cancer: the CAP and ProtecT RCTs

Ling Yang, Oxford
Comprehensive assessment of H. pylori antigens and other infectious pathogens in the aetiology of gastric and oesophageal cancer subtypes

Julian Peto, LSHTM
Current environmental asbestos exposure in young people and future mesothelioma risks in Britain: Extension of The Inhaled Particle Study

Marijn de Bruin, University of Aberdeen
Improving methodology in the design, conduct, and reporting of behavioural smoking cessation trials: three systematic reviews building on a current CRUK evidence review

Brendan Delaney, Imperial College London
Demonstrating the feasibility of a Learning Health System for cancer diagnosis in Primary Care

Chris Cardwell, Queen's University Belfast
Using newly developed screening methods to systematically assess the association between prescription medications and cancer risk

Population Research Postdoctoral Fellowship

David Muller, Imperial College London
Probing the mysterious epidemiology of kidney cancer incidence and survival

Caroline Wright, University of Bristol
Longitudinal patterns and predictors of multiple cancer-risk behaviours among UK adolescents

Samantha Quaife, University College London
Uptake of lung cancer screening with high-risk groups: harnessing psychological targets for intervention

Catalyst Award

Jack Cuzick, Queen Mary, University of London
Understanding the mechanisms and benefit risk of aspirin chemoprevention of cancer through population research - Aspirin for Cancer Prevention Collaboration (AfCPC)

Cancer Prevention Innovation Grants

Danae Manika, QMUL
Stealth Marketing

Clare Stevinson, Loughborough
Don't Stop Now

Shaunna Burke, Leeds
Geocaching

Louise Mansfield, Brunel
Wating Game

Karen Poole, Surrey
Fabric

International Innovation Grants

Caitlin Notely, University of East Anglia
Project HATCH – Staying Healthy AfTer Childbirth A cross-national study to support smoking abstinence and inter-related cancer-prevention behaviours among postpartum women

David Conway, University of Glasgow
Advancing cancer prevention pricing interventions across the UK and US: Optimising message framing

Noreen Mdege, University of York
Changing How People Think and Feel about Cancer Prevention Behaviors: Translating Neuroscience into Population Health

Tapio Paljarvi, Cardiff University
RESET Sleep: Regulating Exercise, Substance Use, and Eating through Sleep

Fiona Johnson, University of Strathclyde
Incentivized smoking cessation for tobacco treatment-resistant diabetics

​​Programme Awards

Professor Jude Fitzgibbon, Queen Mary, University of London
Improving outcome for patients with Poor Risk Acute Myeloid Leukaemia

Professor Pascal Meier, Institute of Cancer Research
Harnessing cell death mechanisms to overcome treatment resistance and improve tumour immunity

Professor Karim Labib, University of Dundee
Novel Genome Integrity Pathways that regulate DNA Replication Termination in Metazoa

Professor Derek Mann, Newcastle University
Towards targeting neutrophils in hepatocellular carcinoma

Professor Fiona Watt, King's College London
An integrated analysis of oral squamous cell carcinoma development and progression

Professor Graham Packham, University of Southampton
B-cell receptor signalling in B-cell malignancies: Identifying strategies for optimal therapeutic intervention based on common and distinct responses

Professor Peter McHugh, University of Oxford
The MBL DNA Repair nucleases – from basic biology to therapeutic inhibition

Renewals

Professor David Barford, MRC Laboratory of Molecular Biology
Molecular Mechanisms of the APC/C and Cell Cycle

Professor Laurence Pearl, University of Sussex
Structural Biology of DNA Damage Response and Repair Mechanisms

Professor Daniel Longley, Queen's University Belfast
Impact of chemotherapy on anti-cancer immunity in molecularly-stratified subgroups of colorectal cancer- Supported by the Bobby Moore Fund

Professor Jonathon Pines, Institute of Cancer Research
The role of the Spindle Assembly Checkpoint in Genomic Stability

Professor Christopher Lord, Institute of Cancer Research
Cancer susceptibility genes

Professor Dale Wigley, Imperial College London
Structural and mechanistic studies of proteins involved in human DNA double-strand break repair

Dr Ketan Patel, MRC Laboratory of Molecular Biology
Understanding how alcohol and endogenous aldehydes promote carcinogenesis

Professor Kevin Harrington, Institute of Cancer Research
Optimising Radiation Therapy in Head and Neck Cancers Using Functional Image-Guided Radiotherapy and Immuno-oncology Agents

Professor Grant Stewart, University of Birmingham
Characterising novel regulators of the PI-3-kinase-like kinase-dependent DNA damage response and their role in preventing human disease and cancer

Professor Steven Clifford, Newcastle University
Biomarker-driven individualisation of medulloblastoma therapy

Dr Mariann Bienz, MRC Laboratory of Molecular Biology
Defining molecular interactions between tumor suppressors and oncogenes in the Wnt signalling pathway

Programme Foundation Awards

Dr Mathew Coleman, University of Birmingham
Investigating the role of protein hydroxylation in cancer

Dr Ian Hitchcock, University of York
Dissecting the Roles of the Thrombopoietin Receptor in Myeloproliferative Neoplasms: Towards the Development of New Therapeutic Agents

Dr Emma Harris, Institute of Cancer Research
Multi-parametric ultrasound imaging for assessment of tumour response to radiotherapy

Dr Katrin Ottersbach, University of Edinburgh
Understanding the origin and pathogenesis of MLL-AF4-associated infant leukaemia

Dr Daniel Tennant, University of Birmingham
Pseudohypoxia-led identification of metabolic vulnerabilities in hypoxic tumours to improve patient outcomes

Dr Francesca Ciccarelli, King's College London
Divided and conquered: analysis of patient inter- and intra-tumour genetic heterogeneity to identify dysfunctional processes in oesophageal cancer

Multidisciplinary Project Awards

Dr Melanie Flint, University of Brighton
A reactive oxygen and nitrogen species (ROS/RNS) monitoring system to study their role in cancer

Dr Munitta Muthana, University of Sheffield
Magnetic delivery of anti-cancer magnetosomes using MRI

Dr Francesca Palombo, University of Exeter
Detecting the pathology specific chemo-mechanics of epithelial tissue in dysplastic Barrett’s oesophagus using light scattering

Dr Christopher Dunsby, Imperial College London
Using oblique plane light sheet microscopy to quantify the relationships between morphological plasticity in 3D, ERK signalling and metastasis

Dr Helen Mulvana, University of Glasgow
Development of non-ionising and non-invasive, personalised colorectal cancer staging using novel multimodal contrast agents and magnetomotive ultrasound imaging

Dr Guillaume Salbreux, The Francis Crick Institute
Understanding the biophysical basis of cellular shape change during mitosis

Professor Christofer Toumazou, Imperial College London
Mi-CARE: A Microchip-based diagnostic Companion for Early Detection and Therapeutic Monitoring of Breast Cancer

Cancer Immunology Project Awards

Professor Benjamin Chain, University College London
Deciphering intra-tumoural T cell receptor diversity in TRACERx non-small cell lung cancer and its relation to intra tumour heterogeneity and clinical outcomes

Dr Ann Ager, Cardiff University
Unravelling the relationship between T cell trafficking and cancer immunotherapy

Dr Sarah Walmsley, University of Edinburgh
Neutrophil functional plasticity in glioblastoma; a therapeutic target?

Dr Luisa Martinez-Pomares, University of Nottingham
Specific mannose receptor blockade as a novel tool for reprogramming tumour-associated macrophages for anticancer therapy

Dr Pierre Guermonprez, King's College London
Functional significance of the GM-CSF secreted by tumours for anti-tumoral T cell responses

Professor Rose Zamoyska, University of Edinburgh
Genetic manipulation of Human T cells for use in adoptive T cell therapy

Dr Robert Salmond, University of Leeds
Manipulating T cell signalling to improve anti-tumour immunity

Dr Chengcan Yao, University of Edinburgh
Investigating the immune mechanisms underlying NSAID chemoprevention of colorectal cancer

Immunology Innovation Award

Dr Yin Wu, University College London
Identifying critical pathways regulating autoimmunity in immuno-oncology and arthritis patients. Short title: IPADS (Immune PAthways for Drug Side-effects)

Dr Joanne Konkel, University of Manchester
Does defective wound healing contribute to immune dysregulation in both cancer and arthritis?